Showing results (11-20 of 259) with videos related to

Sort By:
Pageof 26
Current Opinion in Oncology|January 23, 2015
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancerBin-Chi Liao, Chia-Chi Lin, James Chih-Hsin Yang
Expert Opinion on Pharmacotherapy|May 5, 2018
Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?Bin-Chi Liao, Chia-Chi Lin, James Chih-Hsin Yang
Future Oncology (London, England)|July 11, 2013
EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancerHsiang-Fong Kao, Chia-Chi Lin, James Chih-Hsin Yang
JTO Clinical and Research Reports|September 30, 2021
The Role of Interleukin 1β in the Pathogenesis of Lung CancerEdward B Garon, James Chih-Hsin Yang, Steven M Dubinett
Cancer Treatment Reviews|July 22, 2019
Opportunities of circulating tumor DNA in lung cancerTing-Hui Wu, Emily Han-Chung Hsiue, James Chih-Hsin Yang
Journal of Biomedical Science|October 9, 2025
PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLCChia-Chi Hsu, Derek De-Rui Huang, Wei-Hsun Hsu, et al.
Therapeutic Advances in Medical Oncology|April 26, 2019
First-line afatinib for the treatment of <i>EGFR</i> mutation-positive non-small-cell lung cancer in the 'real-world' clinical settingKeunchil Park, Darren Wan-Teck Lim, Isamu Okamoto, et al.
Cancers|July 29, 2025
The Prognostic Role of Tertiary Lymphoid Structures and Immune Microenvironment Signatures in Early-Stage <i>EGFR</i>-Mutant Lung AdenocarcinomaWei-Hsun Hsu, Chia-Chi Hsu, Min-Shu Hsieh, et al.
Therapeutic Advances in Medical Oncology|August 27, 2020
The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutationShang-Gin Wu, Chong-Jen Yu, James Chih-Hsin Yang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutationsSheng-Kai Liang, Jen-Chung Ko, James Chih-Hsin Yang, et al.
Pageof 26